Applied Molecular Transport logo
Applied Molecular Transport AMTI

Quarterly report 2023-Q3
added 11-09-2023

report update icon

Applied Molecular Transport Net Debt 2011-2026 | AMTI

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Applied Molecular Transport

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-56.5 M -156 M - -12.7 M -20.3 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-12.7 M -156 M -61.4 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
-47.4 M $ 2.11 -13.17 % $ 217 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
-311 M $ 20.52 -2.12 % $ 2.59 B usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
-205 M $ 164.13 0.15 % $ 8.17 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Aytu BioScience Aytu BioScience
AYTU
-19.9 M $ 2.49 -3.11 % $ 15.6 M usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
BridgeBio Pharma BridgeBio Pharma
BBIO
1.44 B $ 64.24 -3.37 % $ 12.3 B usaUSA
BioAtla BioAtla
BCAB
-109 M $ 0.18 -26.92 % $ 8.6 M usaUSA
BioCardia BioCardia
BCDA
212 K $ 1.37 6.2 % $ 29 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
211 M $ 8.61 -1.66 % $ 1.78 B usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
-14.3 M $ 2.4 -3.04 % $ 132 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
-141 M $ 28.29 -0.6 % $ 2.8 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
455 M $ 11.47 -0.43 % $ 742 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-1.04 M - 1.93 % $ 17.4 M usaUSA
Biogen Biogen
BIIB
3.36 B $ 187.68 -2.16 % $ 27.5 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
BioVie BioVie
BIVI
-17.2 M $ 1.38 -0.01 % $ 2.04 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
-13.9 M $ 2.91 2.83 % $ 908 M israelIsrael
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
-1.3 B $ 60.68 -1.7 % $ 11.6 B usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
32.8 B $ 62.54 0.27 % $ 127 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
-1.92 M $ 10.85 -0.5 % $ 447 M usaUSA
BioNTech SE BioNTech SE
BNTX
-973 M $ 109.85 -0.34 % $ 27.2 B germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
Aravive Aravive
ARAV
-49.6 M - -13.39 % $ 1.45 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
73 M $ 1.63 -2.69 % $ 4.13 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
-135 M $ 8.6 1.9 % $ 1.39 B britainBritain
Athira Pharma Athira Pharma
ATHA
-47.2 M - - $ 269 M usaUSA